One of the examples you give above is J and J... with someone of that magnitude its very similar to a JV where SNT supply their asset SNT 9465 to J and J for continued Development in an early case or later for Manufacturing and Distribution through their already existing Manufacturing , Warehousing , Distribution , Sales/Marketing and Admin.
SNT are just too small to carry out a Global Manufacturing and Delivery system let alone the time it takes to set up meetings with Government and Private Hospital Procurement ,, where as J&J have 140,000 employees globally and a Global Supply Chain that manufactures in 70 countries and supply over 140 countries with medical care products,,,
In turn there may be several additional J&J licensees. eg J and J own the 5% to 15% Hydrogen Peroxide Patent dose regime for acne, (under 5% does very little and over 15% can cause a reaction) and J&J license that dose formulation to circa 1100 different brand manufacturers.
So although SNT give up some control they benefit through the existing Global Supply Chain and Big Pharma are great at protecting their interests and IP, so no poor imitations/ knock offs.
I'm certainly in the camp as many SH, that the longer The Skin Scarring Division remains under development with SNT the greater the value,,,
Dermal simple external skin application is a low bar for regulatory approval ,, if you can show "any benefit with no harm" then regulatory approval is incoming..
The real value comes with a "Claim" derived from the empirical data gained through Clinical Trialing and identifying the mechanism of action..
eg SNT reduces scar tissue by XXXX over XXX period of application... plus this is a highly visual treatment easily identifiable Treatment for INVESTORs to understand.Noted was Fiona's effort to tame her smile when Gary mentioned "Skin scaring attracts a whole new group of investors "with Cash" " it was as if Fiona knew exactly the right people or people who had made themselves known to her ..
@ivory1 do you know if Canaccord were the financiers for Liquid Skin?
With the success that Fiona has already rightly enjoyed from the returns on "Liquid Skin" you can be sure if she were to contact the same commercialisation team utilised previously "All of them" would want to be part of SNT 9465... IMHO a heck of a lot has been de risked
1, SNT 9465 has undergone 2 years of Pre Clinical Trialing
2, SNT have already Patented SNT 9465
3 SNT are about to invest in further Trialing
4 Fiona simply just doesn't need to pursue sub par Treatments
5 we have Australian of the Year as the Principal Investigator
Back to Garage ,
Rest Up ,,,we have another Webinar Presentation tomorrow SNT 5505...NZT
Honestly can't believe SH are selling down to the Buyers??? 5m shares Traded today on Price Sensitive News?? selling down ?? just load and wait for the Buyers to pay you ask??? not advice just plain common sense
Add to My Watchlist
What is My Watchlist?
